Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program
Background: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. Methods: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the ProfiLER progr...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Elsevier
2022
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/af51f8a698dc4ce7a25e81ac463e3700 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|